You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: March 2024 to July 2025

AbstractFullPdf
Mar 202412431247611
Apr 2024623626377
May 2024493497220
Jun 2024315319186
Jul 2024439446187
Aug 2024322323141
Sep 2024307314137
Oct 2024504508164
Nov 2024496497166
Dec 2024433438165
Jan 2025437438189
Feb 2025507510199
Mar 2025315315157
Apr 2025333333139
May 2025347348200
Jun 202517217381
Jul 2025110
Total728773333319